Article

Anticancer Activity of Elytraria acaulis L. Extracts on Triple Negative Breast Cancer Cell Line

Suresh Babu Bastipati1, Chepuri Kalyani1, Chidepudi Devi Sri Lalitha Naga Tulasi1, Lavudi Saida1★★ Corresponding author

  1. 1Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, Telangana, INDIA.

CORRESPONDENCE

Lavudi Saida

Centre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University, Hyderabad, Telangana, INDIA.

lavudisaida@gmail.com

Received: 03-07-2021; Revised: 11-08-2021; Accepted: 17-09-2021.

Volume 11, Issue 4 · pp. 354–357 · PUBLISHED · DOI: 10.5530/ijpi.2021.4.63

View on IJPI original site ↗

ABSTRACT

Objectives: In the present study, the anticancer potential of the plant extracts of Elytraria acaulis L. (E. acaulis L.) were investigated on human breast cancer cells (MDAMB-231). Methods: Different organic solvent extracts of E. acaulis L. were prepared using methanol, ethanol, ethyl acetate and hexane. The cytotoxicity of plant extracts were evaluated by MTT assay (-(4, 5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) against MDA MB-231cells. The apoptosis associated morphological changes were also observed with the help of propidium iodide staining method. Results: Of all the solvent extracts, methanol extract has shown the highest activity and its IC50 concentration was found to be 80.8±2.08 μg/ml. The anticancer drug Cis-diammineplatinum (II) dichloride was considered as a standard. Conclusion:In further the bioactive compound should be isolated from the methanol crude extract, which is responsible for the cytotoxic effects.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Bastipati, S. B., Kalyani, C., Tulasi, C. D. S. L. N., & Saida, L. (). Anticancer Activity of Elytraria acaulis L. Extracts on Triple Negative Breast Cancer Cell Line. International Journal of Pharmaceutical Investigation, 11(4), 354–357. https://doi.org/10.5530/ijpi.2021.4.63